NOTICE OF MEETING AND AGENDA Enforcement and Compounding Committee Meeting September 16, 2014

Contact Person: Laura Hendricks

(916) 574-7918

This committee meeting is open to the public and is accessible to the physically disabled. A person who needs a disability-related accommodation or modification in order to participate in the meeting may make a request by contacting Laura Hendricks at (916) 574-7918, by emailing laura.hendricks@dca.ca.gov or sending a written request to Ms. Hendricks at the Board of Pharmacy, 1625 N. Market Blvd., Suite N-219, Sacramento, CA 95834. Providing your request at least five business days before the meeting will help to ensure availability of the requested accommodation.

Note: Pharmacists and pharmacy technicians who attend the full committee meeting can be awarded two hours of CE, in accordance with the board's CE policy. A maximum of four CE hours can be earned each year by attending the meetings of two different board committees.

DATE: September 16, 2014

PLACE: DCA Headquarters Building Two

1747 N. Market Boulevard, Room 186

Sacramento, CA 95834

This meeting may be cancelled without notice. For verification of the meeting, call (916) 574-7900 or access the Board's Web site at www.pharmacy.ca.gov.

Discussion and action may be taken on any item on the agenda. The committee may discuss agenda items in any order. Board members who are not on the committee may attend, but may not vote. Time limitations for discussion and comment will be determined by the committee chair.

Agenda

Call to Order 10:15 a.m.

I. Public Comment on Items Not on the Agenda/Agenda Items For Future Meetings Note: The committee may not discuss or take action on any matter raised during this public comment section that is not included on this agenda, except to decide whether to place the matter on the agenda of a future meeting. [Government Code Sections 11125, 11125.7(a)]

II. <u>Enforcement Matters</u>

- a. Evaluation of 16 CCR section 1744 Regarding Required Warning Labels on Prescription Container Labels
- b. Request for Discussion Regarding the Need for Health and Safety Code Section 11164.5(a), Approval to Receive Electronic Prescriptions for Controlled Substance Prescriptions
- c. Discussion of a Proposed Regulation for Pharmacies Aimed at Reducing Losses of Controlled Substances
- d. General Discussion Regarding the Use of Automated Technology in Hospitals and Skilled Nursing Facilities and the Tools for Identification of Medication Diversion from These Units
- e. Discussion Regarding the Drug Enforcement Administration's Regulations for the Take Back of Prescription Medication
- f. Discussion of Rescheduling of Hydrocodone to Schedule II
- g. Discussion of Rescheduling of Tramadol to Schedule IV
- h. Update on the Alternative Process for Pharmacists to Become Registered to Access CURES
- i. Presentation by Rita Shane, PharmD, FASHP, FCSHP on Medication Reconciliation in Health Care Facilities

III. Compounding Matters

- a. Discussion Regarding FDA's Expectations for Human Drug Compounders
- Request By Kaiser Permanente for Clarification Regarding End-Product Testing as Required by 16 CCR section 1751.7
- c. Results of the Board's Implementation and Inspections of California Sterile Compounding Facilities
- d. Data on Violations Found During Out of State Compounding Inspections
- e. Recalls of Compounded Drugs Throughout the United States

IV. Remaining Meeting Dates For 2014

V. Future Meeting Dates

ADJOURN 3:00 p.m.